Patents by Inventor Valeria Marigo
Valeria Marigo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230242568Abstract: Embodiments of the invention are directed to new polymer linked multimeric guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces.Type: ApplicationFiled: September 1, 2022Publication date: August 3, 2023Applicant: MIRECA MEDICINES GMBHInventors: Hans-Gottfried Genieser, Frank SCHWEDE, Andreas RENTSCH, Valeria MARIGO
-
Publication number: 20220402964Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.Type: ApplicationFiled: August 8, 2022Publication date: December 22, 2022Applicant: Graybug Vision, Inc.Inventors: Hans-Gottfried Genieser, Frank SCHWEDE, Andreas RENTSCH, Per EKSTRÖM, Valeria MARIGO, Francois PAQUET-DURAND
-
Patent number: 11407781Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.Type: GrantFiled: June 29, 2017Date of Patent: August 9, 2022Assignee: Graybug Vision, Inc.Inventors: Hans-Gottfried Genieser, Frank Schwede, Andreas Rentsch, Per Ekström, Valeria Marigo, Francois Paquet-Durand
-
Publication number: 20210317156Abstract: Embodiments of the invention are directed to new polymer linked multimeric guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that modulate the cGMP-signaling system, preferably having activating properties, and more preferably being activators of cGMP dependent protein kinase (PKG), and related monomeric precursors thereof. The invention is also directed to related monomeric compounds, which may also show modulating activity and/or may serve as monomeric precursors of the multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications e.g. on chip surfaces.Type: ApplicationFiled: August 31, 2017Publication date: October 14, 2021Applicant: MIRECA MEDICINES GMBHInventors: Hans-Gottfried GENIESER, Frank SCHWEDE, Andreas RENTSCH, Valeria MARIGO
-
Publication number: 20190292214Abstract: Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3?, 5?-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related monomeric compounds, which may serve as monomeric precursors of the multimers, and/or also show itself inhibitory activity and/or impact the inhibitory activity of the related multimers. The invention further relates to the use of such compounds as reagents for signal transduction research and as modulators of cyclic nucleotide-regulated binding proteins and isoenzymes thereof, and as ligands for affinity chromatography, for antibody production or for diagnostic applications, e.g., on chip surfaces.Type: ApplicationFiled: June 29, 2017Publication date: September 26, 2019Applicant: MIRECA MEDICINES GMBHInventors: Hans-Gottfried GENIESER, Frank SCHWEDE, Andreas RENTSCH, Per EKSTRÖM, Valeria MARIGO, Francois PAQUET-DURAND
-
Patent number: 10322087Abstract: The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3?, 5?-monophosphate analogs as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.Type: GrantFiled: March 16, 2016Date of Patent: June 18, 2019Assignee: Mireca Medicines GmbHInventors: Per Ekström, François Paquet-Durand, Pieter Jaap Gaillard, Valeria Marigo, Hans-Gottfried Genieser, Andreas Rentsch, Dragana Trifunovic, Ayse Sahaboglu Tekgoz
-
Publication number: 20180085311Abstract: The invention relates to means and methods of targeted drug delivery of therapeutic agent to and across the blood-ocular barrier. In particular, the invention relates to cyclic guanosine-3?,5 ‘-monophosphate analogues as therapeutic agent for treating retinal diseases. The cGMPSs targeted to the blood-ocular barrier by glutathione-based ligands that facilitate the specific binding to and enhanced internalization by glutathione transporters present on the blood-ocular barrier. The glutathione-based ligands are conjugated to nanocontainers such as liposomes encapsulating the cGMPSs.Type: ApplicationFiled: March 16, 2016Publication date: March 29, 2018Applicant: Mireca Medicines GmbHInventors: Per EKSTRÖM, François PAQUET-DURAND, Pieter Jaap GAILLARD, Valeria MARIGO, Hans-Gottfried GENIESER, Andreas RENTSCH
-
Patent number: 7901686Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: August 3, 2005Date of Patent: March 8, 2011Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.Inventors: Clifford Tabin, Valeria Marigo, Philip W. Ingham, Andrew P. McMahon
-
Publication number: 20080171328Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: ApplicationFiled: August 20, 2007Publication date: July 17, 2008Applicants: The President and Fellows of Harvard College, Imperial Cancer Research Technology LimitedInventors: Clifford Tabin, Valeria Marigo, Philip W. Ingham, Andrew P. McMahon
-
Patent number: 7060450Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: November 13, 2000Date of Patent: June 13, 2006Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology Ltd.Inventors: Clifford Tabin, Valeria Marigo, Philip W. Ingham, Andrew P. McMahon
-
Publication number: 20050282231Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: ApplicationFiled: August 3, 2005Publication date: December 22, 2005Inventors: Clifford Tabin, Valeria Marigo, Philip Ingham, Andrew McMahon
-
Patent number: 6261786Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: July 2, 1996Date of Patent: July 17, 2001Assignees: Imperial Cancer Res. Technology, President & Fellows of Harvard CollegeInventors: Valeria Marigo, Clifford J. Tabin, Philip W. Ingham, Andrew P. McMahon